Influenza Vaccines - Research News and Information

Saturday, January 10, 2009

Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines.

26 Nov 2008 Influenza B virus is an important cause of acute upper respiratory disease in humans. Vaccination is the primary method of control of influenza related disease, yet vaccine methodology and production technology have not changed in over 40 years. In ... Read more...

Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

19 Nov 2008 Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a ... Read more...

Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria.

30 Oct 2008 The hemagglutinin (HA) of influenza A virus plays an essential role in mediating the entry of the virus into host cells. Here, recombinant full-length HA5 protein from a H5N1 isolate (A/chicken/hatay/2004(H5N1)) was expressed and purified from the ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Influenza Vaccines'

These are the very latest articles for this heading:

• Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. 26 Nov 2008
• Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. 19 Nov 2008
• Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. 30 Oct 2008
• Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. 30 Oct 2008
• Influenza vaccine: got it? Give it! 13 Oct 2008
• Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season. 8 Oct 2008
• Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. 7 Oct 2008
• Influenza vaccine 2008-2009. 4 Oct 2008
• Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. 29 Sep 2008
• Toward a broadly protective influenza vaccine. 29 Sep 2008
• Universal influenza vaccination and live attenuated influenza vaccination of children. 29 Sep 2008
• Vaccines against pandemic influenza: what can be done before the next pandemic? 29 Sep 2008
• Preparing for the next influenza pandemic. 29 Sep 2008
• Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. 29 Sep 2008
• Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. 29 Sep 2008
• CDC: older kids should get annual flu vaccine, too. 29 Sep 2008
• Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. 29 Sep 2008
• [New evaluation methods of vaccine safety] 29 Sep 2008
• [Influenza vaccine] 29 Sep 2008
• Making the flu vaccine. Outflanking a virus. 29 Sep 2008

See a longer list of these articles.

Technical information about 'Influenza Vaccines'

Definition: Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.

Registry Number: 0

Descriptor UI: D007252

Alternative terms: Influenza Vaccines; Vaccines, Influenza; Influenzavirus Vaccines; Vaccines, Influenzavirus; Influenza Virus Vaccines; Vaccines, Influenza Virus; Virus Vaccines, Influenza; Flu Vaccines; Vaccines, Flu; Influenza Vaccine; Vaccine, Influenza; Trivalent Live Attenuated Influenza Vaccine; LAIV vaccine; vaccine, LAIV; FluMist; MedImmune Vaccines Brand of Trivalent Live Attenuated Influenza Vaccine; CAIV-T vaccine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D20.215.894.899.302;

History Note: 2005 (1963)

Technical Notes: coordinate IM with specific influenza virus or virus subtype /immunol (IM); SCR records for several specific influenza vaccines are also available; not for Haemophilus influenzae vaccines ( = HAEMOPHILUS VACCINES)